Adjuvant taxanes and the development of breast cancer-related arm lymphoedema

2015 ◽  
Vol 102 (9) ◽  
pp. 1071-1078 ◽  
Author(s):  
M. Cariati ◽  
S. K. Bains ◽  
M. R. Grootendorst ◽  
A. Suyoi ◽  
A. M. Peters ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Arm Lymphoedema

Breast cancer treatment‐related arm lymphoedema and morbidity: A 6‐year experience in an Australian tertiary breast centre

2021 ◽  
Author(s):  
Yang Yang Huang ◽  
Pei Yinn Toh ◽  
Catherine Hunt ◽  
Joshua Tzi Wei Lin ◽  
Roshi Kamyab ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Arm Lymphoedema

scholarly journals Breast cancer related arm lymphoedema and supportive care in oncology

2011 ◽  
Vol 54 ◽  
pp. e165
Author(s):  
C. Boiron ◽  
A. Bourassin
Keyword(s):  
Breast Cancer ◽  
Supportive Care ◽  
Arm Lymphoedema

scholarly journals Arm lymphoedema and upper limb impairments in sentinel node-negative breast cancer patients: A one year follow-up study

The Breast ◽  
2016 ◽  
Vol 29 ◽  
pp. 102-108 ◽  
Author(s):  
An De Groef ◽  
Marijke Van Kampen ◽  
Elena Tieto ◽  
Petra Schönweger ◽  
Marie-Rose Christiaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Upper Limb ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Follow Up Study ◽  
Node Negative Breast Cancer ◽  
Arm Lymphoedema ◽  
One Year

Lymphedema of breast cancer: risk factor and treatment

2015 ◽  
Vol 3 (4) ◽  
pp. 306-321
Author(s):  
Ana H. Losken ◽  
Elisa Mullan
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Cancer Treatment ◽  
Breast Cancer Risk Factor ◽  
Breast Cancer Treatment ◽  
Breast Cancer Surgery ◽  
Secondary Lymphedema ◽  
Lymph Node Transfer ◽  
Arm Lymphoedema ◽  
Chronic Lymphedema

One of the well-known complication of breast cancer treatment is secondary lymphedema; an accumulation of protein-rich interstitial fluid due to the insufficient capacity of the lymphatic system. Lymphedema are affects about 20-30% of women following breast cancer treatment and the risk factors associated with lymphedema development after breast cancer surgery and or radiotherapy are not well established. Early diagnosis and treatment is considered important for successful management of breast cancer related arm lymphoedema. The objective of this study is to assess the value of risk factor and treatment modality of lymphedema. Electronic searches were conducted in MEDLINE®, EMBASE, CINAHL®, and Social Sciences Citation Index. Articles were included where researchers used qualitative research methods and when a comprehensive description of methods and the study's findings were provided. Among 1210 articles, 30-37% developed lymphedema and 45% associated with incresead body mass index (BMI), 53% related with higher stage of disease. Furthermore; 74% strongly step rise with the number of involved lymph nodes; 41% in comorbid diseases, and the time after surgery showed significant correlation with the development of lymphedema in 32%. Suction-assisted protein lipectomy (SAPL) has been shown to safely and effectively reduce the solid component of swelling in chronic lymphedema and microsurgery procedures, including lymphaticovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT), have been shown to be effective in the management of the fluid component of lymphedema and allow for decreased garment use.

Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer

2004 ◽  
Vol 73 (2) ◽  
pp. 133-139 ◽  
Author(s):  
Lone Gothard ◽  
Paul Cornes ◽  
Judith Earl ◽  
Emma Hall ◽  
Julie MacLaren ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin E ◽  
Randomised Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Arm Lymphoedema

scholarly journals A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment

2007 ◽  
Vol 18 (4) ◽  
pp. 639-646 ◽  
Author(s):  
A.L. Moseley ◽  
C.J. Carati ◽  
N.B. Piller
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Arm Lymphoedema

Sclerodermiform aspect of arm lymphoedema after treatment with docetaxel for breast cancer

2007 ◽  
Vol 21 (8) ◽  
pp. 1131-1133 ◽  
Author(s):  
S Vignes ◽  
B Lebrun-Vignes
Keyword(s):  
Breast Cancer ◽  
Arm Lymphoedema

Exploring patient perception of success and benefit in self-management of breast cancer-related arm lymphoedema

2016 ◽  
Vol 20 ◽  
pp. 173-183 ◽  
Author(s):  
Eunice Jeffs ◽  
Emma Ream ◽  
Amanda Shewbridge ◽  
Siobhan Cowan-Dickie ◽  
Diana Crawshaw ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Patient Perception ◽  
Self Management ◽  
Arm Lymphoedema

scholarly journals Factors influencing efficacy of complete decongestive treatment in patients with breast cancer-linked arm lymphoedema

2021 ◽  
Vol 52 (2) ◽  
pp. 132-137
Author(s):  
Dragana Bojinović-Rodić ◽  
Samra Pjanić ◽  
Tamara Popović ◽  
Tatjana Nožica-Radulović
Keyword(s):  
Breast Cancer ◽  
Predictive Factors ◽  
Linear Regression Analysis ◽  
Breast Tumour ◽  
Multivariate Linear Regression Analysis ◽  
Malignant Breast ◽  
History Of ◽  
The Mean ◽  
Arm Lymphoedema ◽  
Mean Compliance

Background/Aim: The most recommended form of lymphoedema therapy is complete decongestive treatment (CDT). Efficacy of CDT in patients with arm lymphoedema related to malignant breast tumour has reported in many studies, but the predictive factors of outcome of this therapy have not been yet sufficiently investigated. The purpose of this research was to identify predictive factors of efficacy of CDT in patients with breast cancer-linked arm lymphoedema throughout the intensive phase of therapy. Methods: The prospective study included 51 patients with breast cancer-linked arm lymphoedema who were subjected to a 3-week program of CDT. Patients' clinical and demographic features, breast cancer treatment characteristics, lymphoedema and CDT characteristics were collected and assessed for their prognostic value. The influence of certain predictors on the degree of lymphoedema reduction was evaluated by multivariate linear regression analysis. Results: Mean age was 58.1 ± 8.0 (95 % CI: 55.8 - 60.3), median of BMI was 28.4 kg/m2 (95 % CI: 27.2 - 29.6). The average duration of lymphoedema was 36.5 ± 43.9 months (95 % CI: 24.1 - 48.8). The mean size of lymphoedema before CDT was 6.99 ± 5.36 %, and the mean degree of lymphoedema reduction was 63.7 ± 28.6 %. The mean compliance to bandages was 217.5 ± 97.8 hours (95 % CI: 190.0 - 245.0) and 7 (13.7 %) patients had a history of erysipelas of the ipsilateral arm. When observing each individual predictor, statistically most significant contribution showed the size of lymphoedema before the therapy (p < 0.001), then history of erysipelas (p < 0.01), and patients' age (p < 0.05). Conclusion: Size of lymphoedema before treatment is the most crucial prognostic factor of the efficacy of CDT in the patients with breast cancer-linked arm lymphoedema. The present study also identified history of erysipelas and patients age as independent predictors of the CDT efficacy.

Sign in / Sign up

Export Citation Format

Share Document